Triple KRAS Pathway Blockade Drives Complete Regression of Pancreatic Tumors in Preclinical Tests
Spanish researchers report a three-drug combo (RMC-6236/daraxonrasib, Afatinib, SD36) that simultaneously targets RAF1 (KRAS downstream), EGFR (upstream) and STAT3 signaling, producing complete regression of pancreatic tumors in orthotopic mouse models and patient-derived tissues with no resistance for more than 200 days, suggesting potential clinical trials for pancreatic ductal adenocarcinoma.